A new online survey is aiming to help paint a more comprehensive picture of adult psychedelic use trends around the globe.
The Global Psychedelic Survey began on Friday and will run until June 2. It is expected to collect data from 5,000 or more English-speaking psychedelics users throughout the world.
It is intended to offer researchers, policymakers, advocates and others an improved understanding of psychedelics and their impact on the mental and physical health of users. The data collected may be published in peer-reviewed journals and presented at conferences and other events.
The survey’s sponsors include the Multidisciplinary Association for Psychedelic Studies (MAPS), SABI Mind, Mind Medicine Australia and Tiny. It takes 20-30 minutes to complete and participants will have the chance to win one of three US$500 Amazon gift certificates.
MAPS is happy to announce the launch of the Global Psychedelic Survey. Co-sponsored by MAPS, SABI Mind, Mind Medicine Australia, and Tiny, the survey marks the most comprehensive assessment of psychedelic use amongst adults to date.
Learn more:https://t.co/LkY6rRjz3Q pic.twitter.com/gYIpII56mH
— MAPS (@MAPS) May 19, 2023
Read more: MAPS launches online education program on psychedelics
Read more: Mind Medicine Australia to supply medical psilocybin and MDMA for clinical trials at no cost
MAPS is a renowned non-profit research organization that recently launched an online education program on psychedelics. The organization was featured in the 2022 Netflix documentary series How to Change Your Mind, which examined the history of psychedelic substances and the innovative research conducted on them in recent days.
“The Global Psychedelic Survey will give us crucial information about how most people consume psychedelics, which is outside of clinical research and the medical system,” said Rick Doblin, President and Founder of MAPS.
SABI Mind is a Calgary-based psychedelics company focused on offering ketamine-assisted therapy to help treat physical and mental health disorders. SABI signed a supply agreement with PharmAla Biotech (CSE: MDMA) last May to acquire MDMA for its healing centres as well and later signed another agreement with Optimi Health (CSE: OPTI) in July to obtain a reliable supply of psilocybin and MDMA for those centres.
Mind Medicine Australia is a charitable organization dedicated to treating mental and physical health disorders through psychedelic therapies in Australia. The non-profit secured a supply of MDMA and psilocybin from Optimi in early March which will be shipped overseas in July once Australia’s Authorized Prescriber Scheme enabling physicians to prescribe the psychedelics takes effect.
Tiny is a company headquartered in Victoria, British Columbia that is focused on purchasing businesses through a one-month process it has developed. Tiny has founded 11 companies and has 35 majority-owned companies.
Read more: NIH invests $1.5M in psychedelics research for substance use disorders
Read more: Ohio State University gets DEA approval for psilocybin cultivation and research
A poll conducted in March by Breakthrough Bulletin found that 60 per cent of respondents felt that psychedelic therapies should be regulated throughout the United States and a majority of 53 per cent believed in removing criminal penalties for possessing psychedelic substances.
Another survey by Verywell Mind last October similarly found that 45 per cent of Americans would support legalizing some psychedelic substances for treating mental health conditions under the supervision of a professional.